Role of Cardiac Magnetic Resonance in Heart Failure with Preserved Ejection Fraction

被引：4
作者：
Pathan F. [1 ,2 ]
Puntmann V.O. [2 ]
Nagel E. [2 ]
机构：
[1] Menzies Institute for Medical Research, University of Tasmania, Hobart
[2] Goethe Institute for Experimental and Translational Cardiovascular Imaging, Goethe CVI, Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, Frankfurt am Main
来源：
Current Cardiovascular Imaging Reports | 2018年 / 11卷 / 5期
关键词：
Aortic pulse wave velocity; Cardiovascular magnetic resonance; Diastolic dysfunction; HFpEF; T1/T2; mapping;
D O I：
10.1007/s12410-018-9450-8
中图分类号：
学科分类号：
摘要：
Purpose of Review: Approximately half of the patients presenting with heart failure have preserved ejection fraction. These patients usually have a combination of underlying etiologies and may profit from individualized treatment. Failure of clinical trials without adequate understanding of the underlying problem highlights the need for an in-depth assessment of this complex clinical syndrome. This review seeks to discuss the role of cardiovascular magnetic resonance imaging (CMR) in improving diagnosis and targeted management of heart failure with preserved ejection fraction (HFpEF). Recent Findings: Technical advances in tissue mapping techniques enable a virtual histopathological perspective to detect myocardial disease processes, such as inflammation, infiltration, and fibrosis. Myocardial perfusion imaging enables separation between regional ischemia due to epicardial coronary artery disease (CAD) and microvascular disease. Finally, computation of aortic pulse wave velocity (PWV) provides insight into the effects of the vascular stiffness on the efficiency of cardiac work. Summary: A comprehensive CMR protocol enables identification of the underlying pathophysiology in patients with HFpEF, allows identification of important differential diagnoses in patients with specific diseases, and may lead to imaging-guided precision medicine in HFpEF. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 98 条
[1]  
Dunlay S.M., Roger V.L., Redfield M.M., Epidemiology of heart failure with preserved ejection fraction, Nat Rev Cardiol, 14, 10, pp. 591-602, (2017)
[2]  
Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 3, pp. 251-259, (2006)
[3]  
Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Gong Y., Liu P.P., Outcome of heart failure with preserved ejection fraction in a population-based study, N Engl J Med, 355, 3, pp. 260-269, (2006)
[4]  
Gerber Y., Weston S.A., Redfield M.M., Chamberlain A.M., Manemann S.M., Jiang R., Killian J.M., Roger V.L., A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010, JAMA Intern Med, 175, 6, pp. 996-1004, (2015)
[5]  
Lee D.S., Gona P., Vasan R.S., Larson M.G., Benjamin E.J., Wang T.J., Tu J.V., Levy D., Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute, Circulation, 119, 24, pp. 3070-3077, (2009)
[6]  
Perez de Isla L., Canadas V., Contreras L., Almeria C., Rodrigo J.L., Aubele A.L., Et al., Diastolic heart failure in the elderly: in-hospital and long-term outcome after the first episode, Int J Cardiol, 134, 2, pp. 265-270, (2009)
[7]  
Tribouilloy C., Rusinaru D., Mahjoub H., Souliere V., Levy F., Peltier M., Slama M., Massy Z., Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study, Eur Heart J, 29, 3, pp. 339-347, (2008)
[8]  
Cleland J.G., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 19, pp. 2338-2345, (2006)
[9]  
Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Anderson S., Donovan M., Iverson E., Staiger C., Ptaszynska A., Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 23, pp. 2456-2467, (2008)
[10]  
Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B., Clausell N., Desai A.S., Diaz R., Fleg J.L., Gordeev I., Harty B., Heitner J.F., Kenwood C.T., Lewis E.F., O'Meara E., Probstfield J.L., Shaburishvili T., Shah S.J., Solomon S.D., Sweitzer N.K., Yang S., McKinlay S., Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, 370, 15, pp. 1383-1392, (2014)
12345678910